Skip to content
RNAWiki
Checking…
All public datasets

Public dataset

Recorded source agreement and disagreement

Show whether sources print one normalized reading, have incompatible units, lack structured comparison context, or contain a context-matched numeric difference.

What this does not mean: agree can mean only that sources print the same normalized reading; it is not clinical-context equivalence, independent replication, or proof. differ requires matching structured context and disjoint comparable values. not_comparable and insufficient_context are not disagreement.
Public rows
1,681
Generated
Schema version
source-consensus/2

Coverage

What this run contains

Compared medicine fields
1,681
Agree
1,282
Differ
0
Not comparable
12
Insufficient context
387
Fields represented
5
bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution

Method

How the rows were made

  1. Deterministic rules normalize recorded pharmacokinetic readings and compare only like-for-like values.
  2. One normalized printed reading may be agree even when clinical context was not extracted; this reports printed-reading agreement only.
  3. Distinct readings may differ only when their units and denominators are comparable and one matching, non-placeholder population/formulation context was structurally extracted. Otherwise they are insufficient_context.
  4. not_comparable preserves incompatible units or denominators instead of guessing. insufficient_context preserves missing or non-matching structured context instead of manufacturing agreement or disagreement.
  5. The agreement rate describes the distribution of recorded source readings; it is not a probability that a value is true.
  6. Every distinct printed reading retains its unit, population context, source count, and complete source records. The API paginates field rows, never child readings or sources.
  7. documentsExamined is every matching single-substance archive document inspected for that medicine. The generator has no document, reading, or source ceiling, so there is no hidden available-versus-retained remainder.

Limits

Read these before using a row

  • Current label parsing does not structurally extract population or formulation context. Distinct otherwise-comparable readings are therefore insufficient_context, never differ; agree may mean printed-reading agreement only. Source records are complete but are not independent-experiment counts.
  • The current deterministic parser does not structurally extract population or formulation context from these sentences. It records that context as unknown and cannot publish distinct same-unit readings as differ.
  • Neither reading is marked wrong. Population, formulation, route, and other unextracted context may explain the printed difference.
  • Only the recorded fields and source documents in this snapshot are compared.
  • A source count is the number of retained source records in the row, not a count of independent experiments.

Provenance

Source examples

abacavir · bioavailability · agree

15 documents examined; 83% (Unknown: population and formulation context were not structurally extracted from this source sentence.)

FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)
The geometric mean absolute bioavailability of the tablet was 83%.

alemtuzumab · volumeOfDistribution · not_comparable

2 documents examined; 0.18 L/kg (Unknown: population and formulation context were not structurally extracted from this source sentence.); 14.1 L (Unknown: population and formulation context were not structurally extracted from this source sentence.)

FDA_LABEL:4f5f7255-7abc-4328-bd1a-ceaf139ef3e0 (opens source in a new tab)
Distribution After the last 30 mg dose, the mean volume of distribution at steady-state was 0.18 L/kg (range 0.1 to 0.4 L/kg).

abiraterone · halfLife · insufficient_context

31 documents examined; 12 ± 5 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.); 18 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.)

FDA_LABEL:c9eb9b46-f847-40a8-802c-a51b40406d5a (opens source in a new tab)
Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.

Artifact used for this view: data/source-consensus.ndjson. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.

Schema

Fields in the public projection

FieldTypeMeaning
medicineSlugstringStable RNAWiki medicine route key.
fieldstringRecorded pharmacokinetic field being compared.
comparisonStatestringagree (printed-reading agreement), differ (context-matched comparable disjoint values), not_comparable (unit/denominator mismatch), or insufficient_context. Every state remains declared even when its current count is zero.
comparisonReasonsstring[]Deterministic codes explaining the state.
documentsExaminednumberRecorded source documents considered for the field.
sourceCountnumberRecorded source readings represented.
agreementRatenumberShare represented by the leading normalized printed-reading group; not a confidence score or clinical agreement probability.
readingsconsensus-reading[]Complete, untruncated reading groups. Each keeps the printed display, numeric value when parsed, unit, population context, source count, and every source identity, version/effective date or explicit absence, retrieval date, locator, safe link, and excerpt.

Reader

Search and filter the rows

Case-insensitive text search over the public fields named for this dataset.

Exact comparability state.

Exact recorded field key.

Clear

Showing 381–390 of 1,681 matching rows. Filters and search terms remain attached when you move between pages or open the API view.

  1. Projected row 381

    Medicine slug
    deferiprone
    Compared field
    halfLife
    Comparison state
    insufficient_context
    Reason codes
    • STRUCTURED_CONTEXT_MISSING
    Documents examined
    7
    Source count
    7
    Agreement rate
    0.857143
    Recorded readings

    1. 2 hours

      Numeric value
      2
      Unit
      hours
      Source records
      6

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 6 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f057cf4d-b06f-4fbd-aa2e-68c5e4d8a846 (opens source in a new tab)

        Deferiprone label

        Version not recorded · Effective date not recorded

        Elimination The elimination half-life of deferiprone is approximately 2 hours.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:67139215-1154-4e1a-ae15-0f3cd8af5177 (opens source in a new tab)

        Deferiprone label

        Version not recorded · Effective date not recorded

        Elimination The elimination half-life of deferiprone is approximately 2 hours.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:58dd1370-5042-833f-e063-6394a90a0777 (opens source in a new tab)

        Deferiprone label

        Version not recorded · Effective date not recorded

        Elimination The elimination half-life of deferiprone is approximately 2 hours.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d7ea0a84-c328-4636-8cd6-ad75f2074b22 (opens source in a new tab)

        Deferiprone label

        Version not recorded · Effective date not recorded

        Elimination: The elimination half-life of deferiprone is approximately 2 hours.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c4f9e9be-39e7-4940-9cb0-f17772d7e524 (opens source in a new tab)

        Deferiprone label

        Version not recorded · Effective date not recorded

        Elimination: The elimination half-life of deferiprone is approximately 2 hours.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5af1643d-4c6e-4668-ae9b-1046f0ad6d8a (opens source in a new tab)

        Deferiprone label

        Version not recorded · Effective date not recorded

        Elimination The elimination half-life of deferiprone is approximately 2 hours.

    2. 1.8 ± 0.3 hours

      Numeric value
      1.8
      Unit
      hours
      Source records
      1

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 1 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:946718ff-df43-1baa-74d1-e5bcfbe8ad86 (opens source in a new tab)

        Deferiprone label

        Version not recorded · Effective date not recorded

        Elimination The mean ± SD elimination half-life of deferiprone is 1.8 ± 0.3 hours following the administration of FERRIPROX Tablets (twice a day).

  2. Projected row 382

    Medicine slug
    deflazacort
    Compared field
    proteinBinding
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    16
    Source count
    16
    Agreement rate
    1
    Recorded readings

    1. 40%

      Numeric value
      40
      Unit
      %
      Source records
      16

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 16 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:881785a5-41b4-4679-a29b-5d77ca51ca60 (opens source in a new tab)

        Deflazacort label

        Version not recorded · Effective date not recorded

        Distribution The protein binding of the active metabolite of deflazacort is about 40%.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:abf1dba1-cfd8-4a05-aa2b-ffacfbeb9fa9 (opens source in a new tab)

        Deflazacort label

        Version not recorded · Effective date not recorded

        Distribution The protein binding of the active metabolite of deflazacort is about 40%.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ced839ee-1131-45c6-9e38-cc81d85daf1c (opens source in a new tab)

        Deflazacort label

        Version not recorded · Effective date not recorded

        Distribution The protein binding of the active metabolite of deflazacort is about 40%.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fb5350d5-ead1-41f4-8b25-0da0bd7fcffe (opens source in a new tab)

        Deflazacort label

        Version not recorded · Effective date not recorded

        Distribution The protein binding of the active metabolite of deflazacort is about 40%.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2fac1332-0247-1047-e063-6294a90a557f (opens source in a new tab)

        Deflazacort label

        Version not recorded · Effective date not recorded

        Distribution The protein binding of the active metabolite of deflazacort is about 40%.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:14569f71-573e-49fd-b80e-b3b52531b1c8 (opens source in a new tab)

        Deflazacort label

        Version not recorded · Effective date not recorded

        Distribution The protein binding of the active metabolite of deflazacort is about 40%.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:31b347d2-f156-4055-9d8f-7cf0df420296 (opens source in a new tab)

        Deflazacort label

        Version not recorded · Effective date not recorded

        Distribution The protein binding of the active metabolite of deflazacort is about 40%.
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:40818600-3ff0-4c9c-8e31-2001425a7dc9 (opens source in a new tab)

        Deflazacort label

        Version not recorded · Effective date not recorded

        Distribution The protein binding of the active metabolite of deflazacort is about 40%.
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:89365f9f-a7ae-40d3-aecc-e4add75d21c2 (opens source in a new tab)

        Deflazacort label

        Version not recorded · Effective date not recorded

        Distribution The protein binding of the active metabolite of deflazacort is about 40%.
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:18518568-a40b-41cb-91ce-44fbb5557971 (opens source in a new tab)

        Deflazacort label

        Version not recorded · Effective date not recorded

        Distribution The protein binding of the active metabolite of deflazacort is about 40%.
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:459b75a2-3242-3048-e063-6394a90ab882 (opens source in a new tab)

        Deflazacort label

        Version not recorded · Effective date not recorded

        Distribution The protein binding of the active metabolite of deflazacort is about 40%.
      12. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:40a833a4-e029-a99e-e063-6394a90afd50 (opens source in a new tab)

        Deflazacort label

        Version not recorded · Effective date not recorded

        Distribution The protein binding of the active metabolite of deflazacort is about 40%.
      13. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:39854f19-d8be-6438-e063-6394a90a9422 (opens source in a new tab)

        Deflazacort label

        Version not recorded · Effective date not recorded

        Distribution The protein binding of the active metabolite of deflazacort is about 40%.
      14. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f99fde7c-91ac-4d67-bd76-2b18a1d31f7d (opens source in a new tab)

        Deflazacort label

        Version not recorded · Effective date not recorded

        Distribution The protein binding of the active metabolite of deflazacort is about 40%.
      15. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ba749cfb-813d-4799-9e7b-44ede92065f2 (opens source in a new tab)

        Deflazacort label

        Version not recorded · Effective date not recorded

        Distribution The protein binding of the active metabolite of deflazacort is about 40%.
      16. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:77d7525d-89c9-4fde-a6a8-0a463fd6cfeb (opens source in a new tab)

        Deflazacort label

        Version not recorded · Effective date not recorded

        Distribution The protein binding of the active metabolite of deflazacort is about 40%.

  3. Projected row 383

    Medicine slug
    deflazacort
    Compared field
    tMax
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    16
    Source count
    16
    Agreement rate
    1
    Recorded readings

    1. 1 hour

      Numeric value
      1
      Unit
      hours
      Source records
      16

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 16 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:881785a5-41b4-4679-a29b-5d77ca51ca60 (opens source in a new tab)

        Deflazacort label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Absorption After oral administration in the fasted state, the median T max with deflazacort suspension is about 1 hour (range 0.25 to 2 hours).
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:abf1dba1-cfd8-4a05-aa2b-ffacfbeb9fa9 (opens source in a new tab)

        Deflazacort label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Absorption After oral administration in the fasted state, the median T max with deflazacort suspension is about 1 hour (range 0.25 to 2 hours).
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ced839ee-1131-45c6-9e38-cc81d85daf1c (opens source in a new tab)

        Deflazacort label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Absorption After oral administration in the fasted state, the median T max with deflazacort tablets is about 1 hour (range 0.25 to 2 hours).
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fb5350d5-ead1-41f4-8b25-0da0bd7fcffe (opens source in a new tab)

        Deflazacort label

        Version not recorded · Effective date not recorded

        The precise mechanism by which deflazacort exerts its therapeutic effects in patients with DMD is unknown. 12.3 Pharmacokinetics Absorption After oral administration in the fasted state, the median T max with deflazacort tablets is about 1 hour (range 0.25 to 2 hours).
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2fac1332-0247-1047-e063-6294a90a557f (opens source in a new tab)

        Deflazacort label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Absorption After oral administration in the fasted state, the median T max with deflazacort suspension is about 1 hour (range 0.25 to 2 hours).
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:14569f71-573e-49fd-b80e-b3b52531b1c8 (opens source in a new tab)

        Deflazacort label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Absorption After oral administration in the fasted state, the median T max with deflazacort suspension is about 1 hour (range 0.25 to 2 hours).
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:31b347d2-f156-4055-9d8f-7cf0df420296 (opens source in a new tab)

        Deflazacort label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Absorption After oral administration in the fasted state, the median T max with deflazacort tablets or suspension is about 1 hour (range 0.25 to 2 hours).
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:40818600-3ff0-4c9c-8e31-2001425a7dc9 (opens source in a new tab)

        Deflazacort label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Absorption After oral administration in the fasted state, the median T max with deflazacort tablets is about 1 hour (range 0.25 to 2 hours).
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:89365f9f-a7ae-40d3-aecc-e4add75d21c2 (opens source in a new tab)

        Deflazacort label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Absorption After oral administration in the fasted state, the median T max with deflazacort tablets is about 1 hour (range 0.25 to 2 hours).
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:18518568-a40b-41cb-91ce-44fbb5557971 (opens source in a new tab)

        Deflazacort label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Absorption After oral administration in the fasted state, the median T max with deflazacort tablet is about 1 hour (range 0.25 to 2 hours).
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:459b75a2-3242-3048-e063-6394a90ab882 (opens source in a new tab)

        Deflazacort label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Absorption After oral administration in the fasted state, the median T max with deflazacort tablets is about 1 hour (range 0.25 to 2 hours).
      12. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:40a833a4-e029-a99e-e063-6394a90afd50 (opens source in a new tab)

        Deflazacort label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Absorption After oral administration in the fasted state, the median T max with deflazacort suspension is about 1 hour (range 0.25 to 2 hours).
      13. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:39854f19-d8be-6438-e063-6394a90a9422 (opens source in a new tab)

        Deflazacort label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Absorption After oral administration in the fasted state, the median T max with deflazacort suspension is about 1 hour (range 0.25 to 2 hours).
      14. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f99fde7c-91ac-4d67-bd76-2b18a1d31f7d (opens source in a new tab)

        Deflazacort label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Absorption After oral administration in the fasted state, the median T max with deflazacort tablets is about 1 hour (range 0.25 to 2 hours).
      15. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ba749cfb-813d-4799-9e7b-44ede92065f2 (opens source in a new tab)

        Deflazacort label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Absorption After oral administration in the fasted state, the median T max with deflazacort suspension is about 1 hour (range 0.25 to 2 hours).
      16. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:77d7525d-89c9-4fde-a6a8-0a463fd6cfeb (opens source in a new tab)

        Deflazacort label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Absorption After oral administration in the fasted state, the median T max with deflazacort tablets is about 1 hour (range 0.25 to 2 hours).

  4. Projected row 384

    Medicine slug
    demeclocycline
    Compared field
    halfLife
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    5
    Source count
    5
    Agreement rate
    1
    Recorded readings

    1. 16 hours

      Numeric value
      16
      Unit
      hours
      Source records
      5

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 5 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:88e03cb0-25f5-41a5-b77f-58ab8f3be181 (opens source in a new tab)

        Demeclocycline label

        Version not recorded · Effective date not recorded

        The serum half-life ranges between 10 and 16 hours.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e6adaf70-5ff9-4395-bff1-0f332090cb80 (opens source in a new tab)

        Demeclocycline label

        Version not recorded · Effective date not recorded

        The serum half-life ranges between 10 and 16 hours.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:539add06-e0a0-401a-b4f6-20776084aa9c (opens source in a new tab)

        Demeclocycline label

        Version not recorded · Effective date not recorded

        The serum half-life ranges between 10 and 16 hours.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4ff23e3b-e111-47fd-9776-1d89d6da049b (opens source in a new tab)

        Demeclocycline label

        Version not recorded · Effective date not recorded

        The serum half-life ranges between 10 and 16 hours.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:645af8f4-0843-4afb-9ddc-f587f38adb68 (opens source in a new tab)

        Demeclocycline label

        Version not recorded · Effective date not recorded

        The serum half-life ranges between 10 and 16 hours.

  5. Projected row 385

    Medicine slug
    demeclocycline
    Compared field
    proteinBinding
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    5
    Source count
    5
    Agreement rate
    1
    Recorded readings

    1. 40%

      Numeric value
      40
      Unit
      %
      Source records
      5

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 5 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:88e03cb0-25f5-41a5-b77f-58ab8f3be181 (opens source in a new tab)

        Demeclocycline label

        Version not recorded · Effective date not recorded

        The percent of demeclocycline hydrochloride bound to plasma protein is about 40% using a dialysis equilibrium method and 90% using an ultra-filtration method.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e6adaf70-5ff9-4395-bff1-0f332090cb80 (opens source in a new tab)

        Demeclocycline label

        Version not recorded · Effective date not recorded

        The percent of demeclocycline hydrochloride bound to plasma protein is about 40% using a dialysis equilibrium method and 90% using an ultra-filtration method.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:539add06-e0a0-401a-b4f6-20776084aa9c (opens source in a new tab)

        Demeclocycline label

        Version not recorded · Effective date not recorded

        The percent of demeclocycline hydrochloride bound to plasma protein is about 40% using a dialysis equilibrium method and 90% using an ultra-filtration method.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4ff23e3b-e111-47fd-9776-1d89d6da049b (opens source in a new tab)

        Demeclocycline label

        Version not recorded · Effective date not recorded

        The percent of demeclocycline HCl bound to plasma protein is about 40% using a dialysis equilibrium method and 90% using an ultra-filtration method.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:645af8f4-0843-4afb-9ddc-f587f38adb68 (opens source in a new tab)

        Demeclocycline label

        Version not recorded · Effective date not recorded

        The percent of demeclocycline hydrochloride bound to plasma protein is about 40% using a dialysis equilibrium method and 90% using an ultra-filtration method.

  6. Projected row 386

    Medicine slug
    demeclocycline
    Compared field
    tMax
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    5
    Source count
    5
    Agreement rate
    1
    Recorded readings

    1. 4 hours

      Numeric value
      4
      Unit
      hours
      Source records
      5

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 5 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:88e03cb0-25f5-41a5-b77f-58ab8f3be181 (opens source in a new tab)

        Demeclocycline label

        Version not recorded · Effective date not recorded

        The time to reach the peak concentration is about 4 hours.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e6adaf70-5ff9-4395-bff1-0f332090cb80 (opens source in a new tab)

        Demeclocycline label

        Version not recorded · Effective date not recorded

        The time to reach the peak concentration is about 4 hours.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:539add06-e0a0-401a-b4f6-20776084aa9c (opens source in a new tab)

        Demeclocycline label

        Version not recorded · Effective date not recorded

        The time to reach the peak concentration is about 4 hours.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4ff23e3b-e111-47fd-9776-1d89d6da049b (opens source in a new tab)

        Demeclocycline label

        Version not recorded · Effective date not recorded

        The time to reach the peak concentration is about 4 hours.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:645af8f4-0843-4afb-9ddc-f587f38adb68 (opens source in a new tab)

        Demeclocycline label

        Version not recorded · Effective date not recorded

        The time to reach the peak concentration is about 4 hours.

  7. Projected row 387

    Medicine slug
    denosumab
    Compared field
    bioavailability
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    9
    Source count
    4
    Agreement rate
    1
    Recorded readings

    1. 62%

      Numeric value
      62
      Unit
      %
      Source records
      4

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 4 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b1f0590e-f5bb-44ac-99a0-4aa4596c7e54 (opens source in a new tab)

        Denosumab label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Following subcutaneous administration, bioavailability was 62%.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:49d25732-e05d-47e4-98cb-67df04796d4b (opens source in a new tab)

        Denosumab label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Following subcutaneous administration, bioavailability was 62%.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:69e4890d-5dd9-42a5-aa41-ce50635eaed7 (opens source in a new tab)

        Denosumab label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Following subcutaneous administration, bioavailability was 62%.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:628f0998-1206-4001-aeee-18133aa9f3bf (opens source in a new tab)

        Denosumab label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Following subcutaneous administration, bioavailability was 62%.

  8. Projected row 388

    Medicine slug
    denosumab
    Compared field
    halfLife
    Comparison state
    insufficient_context
    Reason codes
    • STRUCTURED_CONTEXT_MISSING
    Documents examined
    9
    Source count
    9
    Agreement rate
    0.555556
    Recorded readings

    1. 25.4 days

      Numeric value
      Not parsed
      Unit
      Not recorded
      Source records
      5

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 5 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e1d80a82-de52-4a34-9df3-609e50667ffb (opens source in a new tab)

        Denosumab label

        Version not recorded · Effective date not recorded

        Elimination Serum denosumab concentrations declined over a period of 4 to 5 months with a mean half-life of 25.4 days (SD = 8.5 days; n = 46).
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b9e32bf7-d70a-4083-8577-c15751c7f769 (opens source in a new tab)

        Denosumab label

        Version not recorded · Effective date not recorded

        Elimination Serum denosumab concentrations declined over a period of 4 to 5 months with a mean half-life of 25.4 days (SD = 8.5 days; n = 46).
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4bf239bb-c467-4add-b7cf-ea666e4fc693 (opens source in a new tab)

        Denosumab label

        Version not recorded · Effective date not recorded

        Elimination Serum denosumab concentrations declined over a period of 4 to 5 months with a mean half-life of 25.4 days (SD = 8.5 days; n = 46).
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:39a0a789-778f-4695-b3a9-61643e6396cd (opens source in a new tab)

        Denosumab label

        Version not recorded · Effective date not recorded

        Elimination Serum denosumab concentrations declined over a period of 4 to 5 months with a mean half-life of 25.4 days (SD = 8.5 days; n = 46).
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:49e5afe9-a0c7-40c4-af9f-f287a80c5c88 (opens source in a new tab)

        Denosumab label

        Version not recorded · Effective date not recorded

        Elimination Serum denosumab concentrations declined over a period of 4 to 5 months with a mean half-life of 25.4 days (SD = 8.5 days; n = 46).

    2. 28 days

      Numeric value
      Not parsed
      Unit
      Not recorded
      Source records
      4

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 4 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b1f0590e-f5bb-44ac-99a0-4aa4596c7e54 (opens source in a new tab)

        Denosumab label

        Version not recorded · Effective date not recorded

        The mean elimination half-life was 28 days.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:49d25732-e05d-47e4-98cb-67df04796d4b (opens source in a new tab)

        Denosumab label

        Version not recorded · Effective date not recorded

        The mean elimination half-life was 28 days.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:69e4890d-5dd9-42a5-aa41-ce50635eaed7 (opens source in a new tab)

        Denosumab label

        Version not recorded · Effective date not recorded

        The mean elimination half-life was 28 days.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:628f0998-1206-4001-aeee-18133aa9f3bf (opens source in a new tab)

        Denosumab label

        Version not recorded · Effective date not recorded

        The mean elimination half-life was 28 days.

  9. Projected row 389

    Medicine slug
    denosumab
    Compared field
    volumeOfDistribution
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    9
    Source count
    5
    Agreement rate
    1
    Recorded readings

    1. 5.2 L

      Numeric value
      5.2
      Unit
      L
      Source records
      5

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 5 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e1d80a82-de52-4a34-9df3-609e50667ffb (opens source in a new tab)

        Denosumab label

        Version not recorded · Effective date not recorded

        Distribution The mean volume of distribution for denosumab was 5.2 L (SD = 1.7 L).
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b9e32bf7-d70a-4083-8577-c15751c7f769 (opens source in a new tab)

        Denosumab label

        Version not recorded · Effective date not recorded

        Distribution The mean volume of distribution for denosumab was 5.2 L (SD = 1.7 L).
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4bf239bb-c467-4add-b7cf-ea666e4fc693 (opens source in a new tab)

        Denosumab label

        Version not recorded · Effective date not recorded

        Distribution The mean volume of distribution for denosumab was 5.2 L (SD = 1.7 L).
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:39a0a789-778f-4695-b3a9-61643e6396cd (opens source in a new tab)

        Denosumab label

        Version not recorded · Effective date not recorded

        Distribution The mean volume of distribution for denosumab was 5.2 L (SD = 1.7 L).
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:49e5afe9-a0c7-40c4-af9f-f287a80c5c88 (opens source in a new tab)

        Denosumab label

        Version not recorded · Effective date not recorded

        Distribution The mean volume of distribution for denosumab was 5.2 L (SD = 1.7 L).

  10. Projected row 390

    Medicine slug
    denosumab-bmwo
    Compared field
    bioavailability
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    4
    Source count
    2
    Agreement rate
    1
    Recorded readings

    1. 62%

      Numeric value
      62
      Unit
      %
      Source records
      2

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 2 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c5a5d750-80be-49cd-b4a6-c8a815956059 (opens source in a new tab)

        Denosumab-Bmwo label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Following subcutaneous administration, bioavailability was 62%.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d378622d-3a13-4918-ae18-3375cd10d270 (opens source in a new tab)

        Denosumab-Bmwo label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Following subcutaneous administration, bioavailability was 62%.

Access

Query or download the projection

View this filtered page as JSONDownload up to 200 filtered CSV rows
GET /api/datasets/source-consensus?limit=10&offset=380

Allowed query parameters

q
Case-insensitive text search over the public fields named for this dataset.
state
Exact comparability state.Values: agree, differ, not_comparable, insufficient_context
field
Exact recorded field key.Values: bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
limit / offset
Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.

Reuse and corrections

Keep the boundary attached

CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.

Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.

Read the correction policy